Powerup Acquisition CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Aspire Biopharma Holdings, Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2025, primarily to include an inadvertently omitted auditor's report.
10-K: Aspire Biopharma Holdings Completes Business Combination, Eyes FDA Fast Track for Sublingual Aspirin
Aspire Biopharma Holdings finalizes its business combination and is gearing up for clinical trials and FDA Fast Track designation for its high-dose sublingual aspirin product.
PowerUp Acquisition Corp.'s 10-K filing outlines its financials, merger agreement with Visiox Pharmaceuticals, and key operational details.